Guardant Health (GH)
NASDAQ:GH

Guardant Health (GH) Stock Forecast & Price Target

1,486 Followers
See the Price Targets and Ratings of:

GH Analyst Ratings

Strong Buy
12Ratings
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Guardant
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GH Stock 12 Months Forecast

Average Price Target

$79.58
▲(65.04% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $79.58 with a high forecast of $99.00 and a low forecast of $50.00. The average price target represents a 65.04% change from the last price of $48.22.
Highest Price Target$99.00Average Price Target$79.58Lowest Price Target$50.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Craig-Hallum
$88.00
Buy
82.50%
Upside
Initiated
Guardant Health initiated with a Buy at Craig-HallumGuardant Health initiated with a Buy at Craig-Hallum
Canaccord Genuity
$99.00
Buy
105.31%
Upside
Reiterated
Guardant Health risk/reward skewed to upside, says CanaccordGuardant Health risk/reward skewed to upside, says Canaccord
Morgan Stanley
$80.00
Buy
65.91%
Upside
Reiterated
Guardant Health (GH) PT Lowered to $80 at Morgan StanleyMorgan Stanley analyst Tejas Savant lowered the price target on Guardant Health (NASDAQ: GH) to $80.00 (from $85.00) while maintaining a Overweight rating.
Bank of America Securities
$75.00
Buy
55.54%
Upside
Reiterated
Guardant Health (GH) PT Lowered to $75 at BofA SecuritiesBofA Securities analyst Derik de Bruin lowered the price target on Guardant Health (NASDAQ: GH) to $75.00 (from $130.00) while maintaining a Buy rating.
CFRA Analyst forecast on GH
Unknown Analyst
Not Ranked
CFRA
$62.00
Sell
28.58%
Upside
Downgraded
CFRA downgrades Guardant Health (GH) to SellCFRA downgraded Guardant Health (NASDAQ: GH) from Buy to Sell with a price target of $62.00 (from $127.00).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

GH Financial Forecast

GH Earnings Forecast
Next quarter’s earnings estimate for GH is -$1.37 with a range of -$1.60 to -$1.02. The previous quarter’s EPS was -$1.58. GH beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.48% of the time in the same period. In the last calendar year GH has Underperformed its overall industry.
Next quarter’s earnings estimate for GH is -$1.37 with a range of -$1.60 to -$1.02. The previous quarter’s EPS was -$1.58. GH beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.48% of the time in the same period. In the last calendar year GH has Underperformed its overall industry.
GH Sales Forecast
Next quarter’s sales forecast for GH is $122.82M with a range of $120.23M to $125.20M. The previous quarter’s sales results were $117.40M. GH beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year GH has Outperformed its overall industry.
Next quarter’s sales forecast for GH is $122.82M with a range of $120.23M to $125.20M. The previous quarter’s sales results were $117.40M. GH beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.83% of the time in the same period. In the last calendar year GH has Outperformed its overall industry.
GH Analyst Recommendation Trends
In the current month, GH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GH average analyst price target in the past 3 months is $79.58
In the current month, GH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GH average analyst price target in the past 3 months is $79.58

GH Stock Forecast FAQ

What is GH’s average 12-month price target, according to analysts?
Based on analyst ratings, Guardant Health’s 12-month average price target is $79.58.
    What is GH’s upside potential, based on the analysts’ average price target?
    Guardant Health has 65.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GH a Buy, Sell or Hold?
          Guardant Health has a conensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Guardant Health’s price target?
            The average price target for Guardant Health is $79.58. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $99.00 ,the lowest forecast is $50.00. The average price target represents 65.04% Increase from the current price of $48.22.
              What do analysts say about Guardant Health?
              Guardant Health’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis